A significant recall has been issued for levothyroxine sodium tablets, a widely prescribed thyroid medication, due to concerns that the pills may not be fully effective. Major Pharmaceuticals, a large supplier of generic medicines, alerted the public after inspections revealed a "subpotent" dose of the drug in the medication. This means the tablets might contain less of the active ingredient than stated on the label, potentially leading to patients receiving a lower dose than prescribed.
The recall, designated as a Class II by the Food and Drug Administration (FDA), indicates that the medication could cause temporary or medically reversible adverse health effects. However, no injuries related to this specific recall have been reported to date. The FDA announced the recall online, providing a list of the affected drugs and their lot codes on its website.
The affected levothyroxine sodium tablets were distributed nationwide by Cardinal Health and Major Pharmaceuticals. They were sold in 10-count blister packs, available individually or in cartons of 100 tablets, in doses ranging from 25 to 150 micrograms. The recalled medications have expiration dates between July 2026 and January 2027.
Levothyroxine is a synthetic form of the thyroid hormone thyroxine, commonly prescribed to treat hypothyroidism, a condition where the thyroid gland does not produce sufficient amounts of thyroid hormone. Annually, more than 22 million prescriptions for this medication are written in the United States. The thyroid gland, a small butterfly-shaped organ in the neck, regulates metabolism by releasing hormones that control the body's energy usage.
An estimated 20 million Americans experience thyroid-related complications, with hypothyroidism being the most common form. This condition is five to eight times more prevalent in women than in men, though the exact reasons are still under investigation, with theories pointing to differences in immune system function. Other risk factors include a family history of thyroid disease and being over the age of 60.
Patients who have received the recalled medication are advised not to discontinue their treatment without first consulting their physician. Information regarding the cause of the manufacturing error has not yet been disclosed, but such issues can arise from problems with production machinery. The FDA's warning and recall details are available on the agency's official website.